Skip to content

A Multicenter, Self-Matched Positive Controlled Clinical Trial Protocol of Continuous Glucose Monitoring System for the Efficacy and Safety of Real-Time Monitoring of Glucose Concentration in Subcutaneous Tissue Fluid in Patients with Diabetes

A Multicenter, Self-Matched Positive Controlled Clinical Trial Protocol of Continuous Glucose Monitoring System for the Efficacy and Safety of Real-Time Monitoring of Glucose Concentration in Subcutaneous Tissue Fluid in Patients with Diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099127
Enrollment
Unknown
Registered
2025-03-19
Start date
2023-12-26
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Gold Standard:1.Fasting Blood Glucose: In a fasting state, if the blood glucose level is equal to or greater than 7.0 mmol/L (126 mg/dL), a diagnosis of diabetes can be made. 2.Oral Glucose Tolerance
Index test:Fasting Blood Gluucose Test Oral Glulose Tolerance Test, OGTT Random Blood Glulose Test Hemoglobin A1c Test

Sponsors

The Second Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with type 1 or 2 diabetes. 2. People aged 18 years or older, regardless of gender. 3. The subjects had adequate venous access and were assessed by the researcher or appropriate staff. 4. Those who sign informed consent to participate in this study voluntarily. 5. The patient had good compliance and could complete the whole clinical trial.

Exclusion criteria

Exclusion criteria: 1. The skin of body parts damaged, scarred, red, or infected. 2. People who are allergic to disinfectants or medical tape, or susceptible to allergies. 3. Patients who were using anticoagulants or had bleeding tendency within one week prior to enrollment. 4. Those who plan to undergo magnetic resonance imaging (MRI) and electronic computed tomography (CT) examinations within 15 days of product use. 5. Pregnant and lactating women. 6. People with mental disorders, cognitive and communication disorders, or high mental stress. 7. Subjects have received clinical study (drug or device) within the past 1 month.

Design outcomes

Primary

MeasureTime frame
Consistency within the error range of the reference value with the control group;Proportion of Zone A+B of Clarke error grid;Proportion of Zone A+B of Consensus error grid; Mean absolute relative difference;

Secondary

MeasureTime frame
Accordance rate ;Sensor stability;CGM system accuracy;Product usability questionnaire;Sensor life;Subgroup analysis;ICGM accuracy evaluation;

Countries

CHina

Contacts

Public ContactYibing Lu

The Second Affiliated Hospital of Nanjing Medical University

yibing.lu@163.com+86 25 5850 9670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026